Additionally, the SMYD3 inhibitor EPZ031686, by reducing the methylation level of ring finger protein 113A (RNF113A), makes SCLC cells more sensitive to alkylating agents and promotes sustained response to chemotherapy (114). This evidence concerns the gene RNF113A and small cell lung carcinoma.